XORTX Therapeutics Inc (XRTX : TSX-V)
Common Stock
$3.20
CAD
+0.27 (9.22%)
Last updated: 2026-06-30
XRTX
XORTX Therapeutics Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+9.22%
1 Month
+1.27%
YTD
-20.00%
Key Statistics
Market Cap
$5.54M
52W High
$9.85
52W Low
$2.42
P/E Ratio
-
50 Day MA
$3.28
200 Day MA
$3.82
Beta
0.15
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/30/2026 | $3.20 | $3.20 | $3.20 | $3.20 | $3.20 | 1,300 |
| 6/23/2026 | $2.93 | $2.93 | $2.93 | $2.93 | $2.93 | 301 |
| 6/17/2026 | $3.05 | $3.05 | $3.03 | $3.03 | $3.03 | 1,806 |
| 6/16/2026 | $3.00 | $3.00 | $3.00 | $3.00 | $3.00 | 308 |
| 6/15/2026 | $3.00 | $3.00 | $2.93 | $3.00 | $3.00 | 2,825 |
| 6/10/2026 | $3.20 | $3.20 | $3.20 | $3.20 | $3.20 | 1,100 |
| 6/5/2026 | $2.90 | $2.90 | $2.90 | $2.90 | $2.90 | 100 |
| 6/4/2026 | $2.82 | $2.82 | $2.82 | $2.82 | $2.82 | 200 |
| 6/3/2026 | $3.02 | $3.02 | $3.02 | $3.02 | $3.02 | 100 |
| 5/29/2026 | $3.22 | $3.22 | $3.16 | $3.16 | $3.16 | 612 |
Analyst Price Targets
Based on analyst covering XRTX
Wall Street analysts forecast XRTX stock price to rise 2431.2% over the next 12 months.
Consensus
No RatingAvg. Target
C$81.00
+2431.2% Upside
Current Price
C$3.20
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on XRTX's historical volatility
30-Day Vol
124.4%
Annualized
90-Day Vol
129.2%
Annualized
Trend (90d)
+48.6%
Annualized drift
90d Mean
C$3.81
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.39 | C$2.21 โ C$5.21 |
| 60 trading days | C$3.59 | C$1.96 โ C$6.59 |
| 90 trading days | C$3.81 | C$1.81 โ C$8.01 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.42M
- Profit Margin
- 0.00%
- ROE (TTM)
- -137.44%
- EPS (Diluted)
- -3.48
- Book Value
- 1.31
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
๐ Recent Splits
1-for-5
Apr 6, 2026
1-for-9
Nov 14, 2023
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About XRTX
Articles Featuring XRTX.V
Latest articles and analysis covering XRTX.V
Why XORTX Therapeutics Inc stock is skyrocketing today
XORTX Therapeutics Inc has gained 9.21% in the last trading session, closing at CA$3.20. This surge is attributed to positive market sentiment and potential growth opportunities as the company navigates recent leadership changes.
Why XORTX Therapeutics Inc stock is skyrocketing today
XORTX Therapeutics Inc's stock has surged by over 9% in a single trading day, reflecting investor optimism amidst recent corporate changes. The appointment of a new co-CEO could signal a shift in strategy and growth potential.
Why XORTX Therapeutics Inc stock is skyrocketing today
XORTX Therapeutics Inc has seen a significant stock price increase of 9.21% today, closing at CA$3.20. Investors are taking note of this movement, even in the absence of recent corporate news.
